Taiwan admits Covid-19 failures after victims’ families file compensation claims
- Law suit from 12 families accuses authorities of being underprepared despite having more than a year with hardly any cases to prepare for a surge in cases
- Central Epidemic Command Centre admits there were not enough tests when the virus started to sweep through the island
The families allege that the authorities were underprepared despite having more than a year during which there were few cases, resulting in unnecessary deaths and suffering.
“Taiwan was effective in sealing its borders, but there is still space for improvement in its defences within its borders,” it said in a statement.
“Because the past pandemic control measures were appropriate, there was no need for large-scale Covid-19 tests, and because of this the surveillance system was not able to uncover asymptomatic carriers. In addition, the public’s willingness to get vaccinated was low.”
Lawyers representing the families presented a request for a national compensation case last week to both the ministry of Health and Welfare, which oversees the Central Epidemic Control Centre, and the Executive Yuan, Taiwan’s cabinet.
A statement from the Executive Yuan on Thursday expressed compassion, but did not take a position on compensation.
“The government expresses our sympathy for the families’ deaths, and as for the legal process of seeking compensation, the Executive Yuan respects their request and will require the responsible authorities to follow the law and provide help accordingly,” it said.
01:16
Queues at Taiwan Covid-19 testing site as the island battles surge in cases
Family members say that at the height of the outbreak, their loved ones did not have access to drugs such as the antibody treatments that are widely used in the US and elsewhere to prevent cases from becoming more serious.
When the outbreak was at its peak in mid-May, the island had no antibody treatments and only 1,800 units of Remdesivir, an antiviral drug, the Central Epidemic Control Centre said. Both are used to treat Covid-19.
Still, it defended its response for the most part, saying it had put many controls in place. “We were able to suppress large-scale community spread and speed up the procurement of vaccines and vaccinations,” it said.
The task force did not respond when asked whether it had decided to buy antibody medications before the May outbreak.
The families also said that drugs such as Remdesivir were not widely used and doctors had to apply for permission from the central health authorities to use it.
The epidemic control centre said it looked at which drugs had received emergency-use approval in 10 of the most developed countries – including US government guidelines, expert opinions and research data – before adding antibody treatments to their guidelines for doctors in early June.
The US Food and Drug Agency approved emergency use of one antibody treatment in November 2020 and another in February of this year.
Taiwan is now recording new daily cases in single digits and has enough Remdesivir on hand to treat about 11,000 patients and antibody treatments for 4,700 people.